The proposed novel INO-1 and INO-2 GBM subgroups also have distinctive gene expression profiles and mutational schemes; upregulation of genes such as PGAM2, IDO2, STAT-1, IRF9, ADAR1, and HLA-E/A in INO-1; and upregulation of PDGFRA, IGF2, VEGFA, FGF18, and MDM2/4 in INO-2, the latter also showing a high frequency of mutations in TTN, MUC16, EGFR, and TP53. Importantly, female patients belonging to INO-1 have a bad prognosis (OS) compared to the INO-2 female subgroup (p = 0.018). The gene discussed is IRF9; the disease is glioblastoma.